The institute will focus on innovative “care and cures” for brain diseases, including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s and other neurodegenerative diseases.
The institute will focus on innovative “care and cures” for brain diseases, including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s and other neurodegenerative diseases.
Collette Edge’s research presentation on Parkinson’s disease and fitness therapy recently won the grand prize for outstanding work at the College of Education.
By Tina Hilding, Voiland College of Engineering and Architecture PULLMAN, Wash. – A WSU research team for the first time has developed a computer algorithm that is nearly as accurate as people are at mapping brain neural networks — a breakthrough that could speed up the image analysis that researchers use to understand brain circuitry.
By Lori Maricle, College of Pharmacy SPOKANE, Wash. – Researchers have reported a 240 percent increase in the brain of the antioxidant glutathione after it is administered via nasal spray. Glutathione deficiency has been documented in a variety of central nervous system disorders, including Parkinson’s disease, multiple sclerosis, autism, Alzheimer’s disease, schizophrenia and bipolar disease.
By Lori Maricle, College of Pharmacy SPOKANE, Wash. – Repairing the brain’s “house-cleaning function,” which could help people with Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS) and 100 other diseases, is the focus of recently funded research at Washington State University.
By Ethan Nash, Voiland College of Engineering & Architecture intern PULLMAN, Wash. – A Washington State University computer science student who uses technology to understand cognitive health in the elderly has received a National Science Foundation (NSF) Graduate Research Fellowship.
By Eric Sorensen, WSU science writer SEATTLE – A neurodegenerative disease drug developed at Washington State University will likely qualify for a federal “fast-track” designation and go into clinical trials next year, said Leen Kawas, CEO of M3 Biotechnology Inc.
By Rebecca Phillips, University Communications science writer PULLMAN, Wash. – An imposter molecule may be misleading doctors who monitor dopamine levels in their patients with Parkinson’s disease.
PULLMAN, Wash. – By 2034, there will be an effective treatment for diseases like Parkinson’s and Alzheimer’s diseases, thanks in part to research conducted at Washington State University.